This Week in Infectious Disease — Jun 18, 2026

Welcome to This Week in Infectious Disease. This week we're covering 10 notable papers spanning major clinical trials in bacterial infections, new data on vaccine effectiveness for COVID-19 and Mpox, and a look at the future of antimicrobial discovery and global disease surveillance. Let's dive in.

We begin with two important clinical trials that could change how we manage common and serious bacterial infections. First, a major question in treating methicillin-susceptible Staphylococcus aureus bacteremia has been the choice between cefazolin and antistaphylococcal penicillins. In The New England Journal of Medicine, an international Bayesian adaptive platform trial provides a clear answer [1]. In this open-label comparison, over 1200 adults with MSSA bacteremia were randomized to either cefazolin or an antistaphylococcal penicillin like flucloxacillin. The primary outcome, 90-day mortality, was 15% in the cefazolin group and 17% in the penicillin group. The analysis confirmed that cefazolin was noninferior, with a high probability of noninferiority at 99.2%. Importantly, from a safety perspective, cefazolin came out ahead. Acute kidney injury occurred in about 14% of patients receiving cefazolin, compared to nearly 20% in the antistaphylococcal penicillin group. This means cefazolin was associated with both non-inferior efficacy and a significantly lower risk of renal toxicity, providing strong evidence to prefer it as first-line therapy for these infections. Shifting from bloodstream infections to the urinary tract, a study in Clinical Infectious Diseases addresses the challenge of oral step-down therapy for complicated UTIs caused by ESBL-producing Enterobacterales [4]. To reduce reliance on carbapenems, researchers in South Korea conducted a multicenter, open-label trial randomizing nearly 300 hospitalized adults who had already improved on 3 to 7 days of IV antibiotics. Patients were assigned to either continue their IV therapy or switch to oral fosfomycin. The results were compelling: clinical cure was achieved in 92.8% of the oral fosfomycin group compared to 95.2% in the IV group, meeting the criteria for noninferiority. Microbiological cure rates and 30-day outcomes were also similar. This trial provides crucial evidence supporting oral fosfomycin as a carbapenem-sparing strategy for these difficult-to-treat infections. Looking further ahead at the antimicrobial resistance crisis, two papers in Science Translational Medicine highlight novel discovery platforms. One study used a deep learning model to screen millions of compounds for activity against Neisseria gonorrhoeae, identifying two promising candidates with novel mechanisms of action that were effective against multidrug-resistant strains in preclinical models [5]. A separate paper describes a new therapeutic approach called targeted complement activation therapy, or T-CAT [6]. This involves engineering monoclonal antibodies that can directly initiate complement activation on the bacterial surface, bypassing common evasion mechanisms. This platform showed efficacy in mouse models of sepsis and pneumonia caused by several major pathogens, offering a potential new strategy against multidrug-resistant organisms.

Next, we turn to vaccines, with important updates on both COVID-19 and Mpox. In JAMA Internal Medicine, researchers from the VISION network provide the first look at the effectiveness of the 2024-2025 COVID-19 vaccine in the United States [7]. This large test-negative case-control study analyzed hundreds of thousands of patient encounters. Among immunocompetent adults, vaccination was associated with an estimated effectiveness of 26% against COVID-related emergency department or urgent care visits, 35% against hospitalization, and 41% against critical illness. The effectiveness against hospitalization was similar in adults aged 65 and older, at 35%. For immunocompromised adults, effectiveness against hospitalization was lower, at 24%. As expected, the authors noted that these effectiveness estimates did wane with time since vaccination. While these numbers are modest, they underscore that the updated vaccine continues to provide meaningful protection against severe disease outcomes. Meanwhile, the emergence of a new Mpox clade in central Africa has raised questions about the protectiveness of existing immunity. A multicountry observational study in The Lancet Infectious Diseases investigated this by measuring neutralizing antibody responses after vaccination or prior infection [3]. The study looked at plasma from individuals who had received the MVA-BN vaccine, the older Dryvax vaccine, or had recovered from a clade IIb infection. The findings suggest that while there is some cross-reactive antibody binding, the neutralizing antibody responses against the emerging clade Ib, as well as the historical clade Ia, were generally low across all vaccinated and previously infected groups. For instance, in those who received the MVA-BN vaccine, detectable neutralization against MPXV was seen in only 3 to 15% of samples. This raises concerns that immunity derived from the 2022 outbreak or current vaccines may not be sufficient to confer robust protection against all Mpox clades, highlighting a potential vulnerability. Finally, a brief commentary in Science outlines progress toward an HIV vaccine, summarizing research in rhesus macaques that provides a potential blueprint for eliciting broadly neutralizing antibodies, a long-sought goal in the field [2].

Finally, we look at papers that provide a broader perspective on global disease burden and the tools used to fight outbreaks. A sobering report from the WHO, published in The Lancet Global Health, updates the global burden of 14 foodborne diarrheal hazards [9]. In 2021 alone, these pathogens were estimated to cause 666 million illnesses and 265,000 deaths from foodborne transmission. The burden is not evenly distributed; the highest rates are in the African region, and children under five are disproportionately affected, with mortality rates over 7 times higher than in older individuals. While the overall burden has decreased since 2000, the report is a stark reminder of the ongoing need to improve food safety worldwide. In the realm of outbreak response, a study in The Journal of Infectious Diseases explores new ways to predict outcomes in patients with Ebola virus disease [10]. We know viral load is a key prognostic factor, but it isn't always perfectly predictive. Using samples from the 2013-2016 West African outbreak, researchers found that measuring the expression of specific host genes could significantly improve prognostic accuracy. Combining the Ebola virus cycle threshold value with the transcript level of a host gene called MS4A4A improved outcome prediction from 87% accuracy with viral load alone to over 91%. The best model, incorporating two host genes and viral load, achieved 100% accuracy in their test set. This approach could one day help clinicians triage patients and better allocate limited resources during an outbreak. Lastly, a paper in Nature describes the Pakistan Genome Resource, a massive biobank of over 173,000 exomes and genomes [8]. The high degree of familial relatedness in this population makes it an incredibly powerful tool for discovering rare, naturally occurring loss-of-function gene variants. By studying individuals who are essentially natural human "knockouts" for certain genes, researchers can mimic pharmacological inhibition, helping to validate new drug targets and accelerate therapeutic development for a wide range of diseases.

If you only have time for one paper this week, make it the trial of cefazolin versus antistaphylococcal penicillins for MSSA bacteremia in The New England Journal of Medicine [1]. It provides definitive, high-quality evidence to support a practice change that improves patient safety by reducing nephrotoxicity without compromising efficacy.

Here are the key takeaways from this week in Infectious Disease. First, for methicillin-susceptible Staph aureus bacteremia, cefazolin should be preferred over antistaphylococcal penicillins, as it offers non-inferior mortality with a significantly lower risk of acute kidney injury. Second, in stable, hospitalized patients with complicated UTIs from ESBL-producing organisms, an oral step-down to fosfomycin is a non-inferior and important carbapenem-sparing strategy. Third, the updated 2024-2025 COVID-19 vaccine provides modest but critical protection against severe disease, reducing the risk of hospitalization by about 35 percent in immunocompetent adults. And finally, be aware that immunity from prior Mpox clade IIb infection or vaccination may not provide robust neutralizing antibody responses against the emerging and more virulent clade Ib, a key consideration for public health surveillance.

That's your roundup for This Week in Infectious Disease. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.